Relay Therapeutics Inc
RLAY
Market Cap$874.3M
Close$
$0.22
94.6% downside
Current Fair Value
94.6% downsideOvervalued by 94.6% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $874.30 Million |
|---|---|
| Enterprise Value | $794.54 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-2.79 |
| Beta | 1.65 |
| Outstanding Shares | 132,821,825 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -2.69 |
|---|---|
| PEG | 11.35 |
| Price to Sales | - |
| Price to Book Ratio | 0.8 |
| Enterprise Value to Revenue | 95.09 |
| Enterprise Value to EBIT | -2.33 |
| Enterprise Value to Net Income | -3 |
| Total Debt to Enterprise | 0.04 |
| Debt to Equity | 0.05 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Relay Therapeutics Inc
2,020 employeesRelay Therapeutics, Inc. operates as a biotechnology company. The Company develops durgs for the treatment of cancer. Relay Therapeutics serves customers in the United States.